CLAIMS

1. Use of nerve growth factor (NGF) or a mutein thereof, said mutein having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6, in the manufacture of a medicament for the prevention or treatment of spasticity in a subject, wherein said NGF or mutein is to be administered intranasally to said subject.

2. The use as claimed in claim 1, wherein said spasticity is caused by a condition selected from cerebral palsy, stroke, traumatic brain injury, amyotrophic lateral sclerosis, primary lateral sclerosis, multiple sclerosis (MS) and hereditary spastic paraplegia (HSP).

3. The use as claimed in claim 1 or claim 2, wherein said NGF is human NGF, more preferably it is recombinant human NGF.

4. The use as claimed in claim 3, wherein said human NGF has the amino acid sequence of SEQ ID NO:1.

5. The use as claimed in any one of claims 1 to 4, wherein said NGF or mutein is to be administered from one to three times a day for a period of treatment of between 7 and 300 days, preferably between 60 and 240 days, more preferably between 100 and 200 days.

6. The use as claimed in any one of claims 1 to 5, wherein the amount of NGF or mutein per each administration is between 5 µg and 1 mg, more preferably between 10 µg and 400 µg, even more preferably between 15 µg and 200 µg.

7. Use of a pharmaceutical composition for intranasal administration comprising NGF or a mutein thereof, said mutein having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6, and at least one pharmaceutically acceptable excipient, in the manufacture of a medicament for the prevention or treatment of spasticity in a subject, wherein said NGF or mutein is to be administered intranasally to said subject.

8. The use as claimed in claim 7, wherein said spasticity is caused by a condition selected from cerebral palsy, stroke, traumatic brain injury, amyotrophic lateral sclerosis, primary lateral sclerosis, multiple sclerosis (MS) and hereditary spastic paraplegia (HSP).

9. The use as claimed in claim 7 or claim 8, wherein said NGF or mutein thereof is present in the composition at a concentration between 5 µg/ml and 1 mg/ml, more preferably between 10 µg/ml and 400 µg/ml, even more preferably between 15 µg/ml and 200 µg/ml.

10. The use as claimed in any one of claims 7 to 9, wherein said pharmaceutical composition comprising, preferably consisting of NGF or mutein thereof, sodium chloride, phosphate buffer and water.

11. The use as claimed in any one of claims 7 to 10, wherein said NGF is human NGF, more preferably it is recombinant human NGF.

12. The use as claimed in claim 7, wherein said human NGF has the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

13. The use as claimed in any one of claims 1 to 6, wherein said spasticity in a subject is caused by stroke or traumatic brain injury, and said NGF or mutein is to be administered to said subject starting between 6 and 10 months, more preferably between 8 and 10 months, more preferably between 9 and 10 months, even more preferably at 9 months after from the occurrence of said stroke or traumatic brain injury.